Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Other Non-Current Assets: 2014-2024

Historic Other Non-Current Assets for Zevra Therapeutics (ZVRA) over the last 9 years, with Dec 2024 value amounting to $384,000.

  • Zevra Therapeutics' Other Non-Current Assets fell 70.12% to $153,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $153,000, marking a year-over-year decrease of 70.12%. This contributed to the annual value of $384,000 for FY2024, which is 308.51% up from last year.
  • Per Zevra Therapeutics' latest filing, its Other Non-Current Assets stood at $384,000 for FY2024, which was up 308.51% from $94,000 recorded in FY2023.
  • Zevra Therapeutics' 5-year Other Non-Current Assets high stood at $438,000 for FY2020, and its period low was $53,000 during FY2022.
  • For the 3-year period, Zevra Therapeutics' Other Non-Current Assets averaged around $177,000, with its median value being $94,000 (2023).
  • As far as peak fluctuations go, Zevra Therapeutics' Other Non-Current Assets plummeted by 87.90% in 2022, and later surged by 308.51% in 2024.
  • Zevra Therapeutics' Other Non-Current Assets (Yearly) stood at $438,000 in 2020, then remained steady at $438,000 in 2021, then slumped by 87.90% to $53,000 in 2022, then soared by 77.36% to $94,000 in 2023, then soared by 308.51% to $384,000 in 2024.